FDA to Hold Public Hearing on Future of Psychedelic Medicine
Published Date: 7/14/2026
Notice
Summary
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Patient Safety and Informed Consent
FDA seeks input on best practices to promote patient safety for psychedelic therapies, including informed consent topics (e.g., risks of psychological distress and power imbalances), screening for medical and psychiatric risk factors (like cardiovascular disease or psychosis), monitoring during and after administration, and reporting ethical violations. The hearing is on September 14, 2026; comments accepted through October 5, 2026.
Access, Coverage, and Payment Considerations
FDA requests input on access issues for potential therapeutic use of psychedelics, including evidence needs for coverage, benefit design, reimbursement and payment models, coordination between providers and payors, workforce and clinic capacity, and telehealth screening and follow-up. The public hearing is September 14, 2026, and written comments are accepted until October 5, 2026.
Training and Credentialing for Providers
The FDA is asking for public input on provider training and credentialing for supervised psychedelic therapies, including curricula, who should develop or endorse training, staffing needs for screening/administration/follow-up, and credentialing or licensure considerations. The public hearing is September 14, 2026, and comments are accepted until October 5, 2026.
Data Collection and Standardization Plans
FDA is seeking input on best practices for data collection and standardization to assess real-world safety and use of psychedelic drugs, including creation of registries, coordination across data sources (EHRs, claims, pharmacy data, patient- and clinician-reported outcomes), common data elements for drug/dosage/indication, adverse event definitions, interoperability, privacy protections, and longitudinal follow-up. The hearing is September 14, 2026; comments accepted through October 5, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
Previous / Next Documents
Previous: 2026-14154 — Hazardous Materials: Notice of Applications for New Special Permits
The Department of Transportation just announced new requests for special permits to handle hazardous materials in different ways. This affects companies that transport dangerous goods by truck, train, ship, or plane, giving them a chance to try new methods safely. If you want to share your thoughts, make sure to comment by August 13, 2026—this could impact how hazardous materials move and possibly save money or time.
Next: 2026-14156 — Hazardous Materials: Notice of Actions on Special Permits
The Department of Transportation just updated special permits for companies handling hazardous materials, making some rules clearer and removing outdated parts. This affects businesses shipping dangerous goods, helping them stay safe and compliant without extra costs. If you want to comment, you’ve got until August 13, 2026, so don’t miss your chance!